Karyopharm Therapeutics INC

Karyopharm Therapeutics reported Q2 2026 results, with total revenue at $33.4 million, and reaffirmed full-year guidance, while advancing its myelofibrosis program towards an sNDA submission.

Karyopharm Therapeutics reported topline data from its XPORT-EC-042 trial for endometrial cancer, which did not meet its primary endpoint, but also announced plans for a myelofibrosis sNDA submission.

Karyopharm Therapeutics Inc. announced a new retention program for key executives and the CFO to incentivize continued service through anticipated company catalysts.

Karyopharm Therapeutics stockholders approved a 3 million share increase to its equity incentive plan and the board authorized a new performance-based retention program for executives.

Karyopharm Therapeutics reported Q1 2026 financial results, highlighting $35.1M in total revenue and progress in key clinical trials for selinexor.

Karyopharm Therapeutics Inc. announced the closing of a private placement and additional open market sales, securing approximately $49.8 million in new capital.

Karyopharm Therapeutics Inc. reported substantial doubt about its ability to continue as a going concern, citing significant operating losses and upcoming debt obligations, despite a slight increase in net product revenue.

Karyopharm Therapeutics Inc. announced its first quarter 2026 financial results, highlighting increased product revenue and ongoing clinical development efforts.

Karyopharm Therapeutics Inc. reported a net loss of $93.8 million for the nine months ended September 30, 2025, but secured $36 million in new financing and debt deferrals in October 2025 to address substantial doubt about its ability to continue as a going concern.

Karyopharm Therapeutics reported a significant net loss in Q2 2025 and disclosed substantial doubt about its ability to continue as a going concern, prompting a review of strategic alternatives.

Karyopharm Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern within the next year.

Karyopharm Therapeutics' Q3 2024 results show a mixed financial picture with decreased product revenue offset by increased license revenue, while the company navigates substantial debt restructuring and going concern challenges.

Karyopharm Therapeutics reports its 10-K filing, highlighting ongoing financial challenges and substantial doubt about its ability to continue as a going concern despite revenue from its drug XPOVIO.

Karyopharm Therapeutics Inc.'s 2023 annual report reveals a year of strategic shifts, financial adjustments, and continued focus on its core oncology programs.

Stuart Poulton, EVP, Chief Development Officer of Karyopharm Therapeutics Inc., sold 189 shares of common stock on July 28, 2026 for $7.10 per share.

Karyopharm Therapeutics Inc. reports the grant of restricted stock units to Director Deepika Pakianathan.

Karyopharm Therapeutics Inc. director Chen Schor was awarded 15,508 restricted stock units under the company's 2022 Equity Incentive Plan.

Karyopharm Therapeutics Inc. reports the grant of 15,508 restricted stock units to Director Zhen Su.

Karyopharm Therapeutics Inc. reports an award of restricted stock units to Director Garen Bohlin, with vesting scheduled for May 21, 2027.

Barry E. Greene, a Director at Karyopharm Therapeutics Inc., has reported the acquisition of 15,508 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.

Karyopharm Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors and vote on equity plan amendments.

Karyopharm Therapeutics Inc. will hold a special stockholder meeting on February 18, 2026, to vote on a proposal to significantly increase its authorized common stock to facilitate future capital raising and strategic initiatives.

Karyopharm Therapeutics is asking shareholders to vote on key proposals, including amendments to equity incentive plans and a stock option exchange program, at its upcoming annual meeting.

Karyopharm Therapeutics is asking stockholders to approve an amendment to its 2022 Equity Incentive Plan to increase the number of shares available for issuance by 450,000.

Karyopharm Therapeutics Inc. will hold its annual meeting on May 29, 2024, to vote on director elections, equity incentive plan amendments, a stock option exchange program, executive compensation, and auditor ratification.

Karyopharm Therapeutics is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans, as well as a one-time stock option exchange program for non-executive employees.

RA Capital Management, along with affiliated entities, has reported a beneficial ownership of 9.9% of Karyopharm Therapeutics Inc. common stock as of June 30, 2026.

Adage Capital Management, L.P. and associated entities have updated their beneficial ownership filing for Karyopharm Therapeutics Inc., reporting a 6.78% stake.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have updated their beneficial ownership filing for Karyopharm Therapeutics Inc., reporting a 6.3% stake.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting a 6.6% beneficial ownership stake in Karyopharm Therapeutics Inc.

Ikarian Capital, LLC and Neil Shahrestani have filed an exit notice, reporting 0% beneficial ownership in Karyopharm Therapeutics Inc.

Acorn Bioventures and Anders Hove have filed a Schedule 13G reporting a 6.7% beneficial ownership stake in Karyopharm Therapeutics Inc.